School of Medicine, Weifang University of Science and Technology, Weifang, 262700, People's Republic of China.
School of Life Science and Technology, Shandong Second Medical University, Weifang, 261053, People's Republic of China.
Int J Nanomedicine. 2024 Jun 4;19:5125-5138. doi: 10.2147/IJN.S460874. eCollection 2024.
Breast cancer is a prevalent malignancy among women worldwide, and malignancy is closely linked to the tumor microenvironment (TME). Here, we prepared mixed nano-sized formulations composed of pH-sensitive liposomes (Ber/Ru486@CLPs) and small-sized nano-micelles (Dox@CLGs). These liposomes and nano-micelles were modified by chondroitin sulfate (CS) to selectively target breast cancer cells.
Ber/Ru486@CLPs and Dox@CLGs were prepared by thin-film dispersion and ethanol injection, respectively. To mimic actual TME, the in vitro "condition medium of fibroblasts + MCF-7" cell model and in vivo "4T1/NIH-3T3" co-implantation mice model were established to evaluate the anti-tumor effect of drugs.
The physicochemical properties showed that Dox@CLGs and Ber/Ru486@CLPs were 28 nm and 100 nm in particle size, respectively. In vitro experiments showed that the mixed formulations significantly improved drug uptake and inhibited cell proliferation and migration. The in vivo anti-tumor studies further confirmed the enhanced anti-tumor capabilities of Dox@CLGs + Ber/Ru486@CLPs, including smaller tumor volumes, weak collagen deposition, and low expression levels of α-SMA and CD31 proteins, leading to a superior anti-tumor effect.
In brief, this combination therapy based on Dox@CLGs and Ber/Ru486@CLPs could effectively inhibit tumor development, which provides a promising approach for the treatment of breast cancer.
乳腺癌是全球女性中常见的恶性肿瘤,恶性肿瘤与肿瘤微环境(TME)密切相关。在这里,我们制备了由 pH 敏感脂质体(Ber/Ru486@CLPs)和小尺寸纳米胶束(Dox@CLGs)组成的混合纳米制剂。这些脂质体和纳米胶束通过硫酸软骨素(CS)修饰,以选择性靶向乳腺癌细胞。
通过薄膜分散法和乙醇注入法分别制备了 Ber/Ru486@CLPs 和 Dox@CLGs。为了模拟实际的 TME,建立了体外“成纤维细胞+MCF-7 条件培养基”细胞模型和体内“4T1/NIH-3T3”共植入小鼠模型,以评估药物的抗肿瘤作用。
物理化学性质表明,Dox@CLGs 和 Ber/Ru486@CLPs 的粒径分别为 28nm 和 100nm。体外实验表明,混合制剂显著提高了药物摄取并抑制了细胞增殖和迁移。体内抗肿瘤研究进一步证实了 Dox@CLGs+Ber/Ru486@CLPs 的增强抗肿瘤能力,包括肿瘤体积更小、胶原沉积较弱以及α-SMA 和 CD31 蛋白表达水平降低,从而产生了更好的抗肿瘤效果。
简而言之,基于 Dox@CLGs 和 Ber/Ru486@CLPs 的这种联合治疗可以有效抑制肿瘤发展,为乳腺癌的治疗提供了一种有前途的方法。